Cancer diagnostics company Biomoda, Inc. (OTC BB: BMOD) (www.biomoda.com) received Notice of Allowance for a U.S. Patent issued today that expands on use of the CyPath® assay to include patient response to cancer therapy during the treatment phase of the disease.
"Our pilot clinical study demonstrated the CyPath® assay's utility as a cancer diagnostic. We expect the unique properties of the CyPath® labeling solution that allow it to bind to cancer cells and cause them to fluoresce can also play a significant role in determining the efficacy of cancer treatment," Biomoda President John Cousins said. "Doctors will be able to take fluid or tissue samples at intervals during chemotherapy, treat them with the CyPath® solution and compare the results to the baseline assay to see if the percentage of cancerous and abnormal cells is moving in the right direction."
Titled "Method for Prognosing Response to Cancer Therapy with 5, 10, 15, 20-Tetrakis (Carboxyphenyl)," U.S. Patent 7,960,138 is a continuation of Biomoda's U.S. Patent 6,838,248, titled "Compositions and Methods for Detecting Pre-Cancerous Conditions in Cell and Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine" which was issued on Jan. 4, 2005.
"One of Biomoda's principal assets is our strong patent portfolio," Biomoda CEO Maria Zannes said. "This patent continues our dual commitments to protecting our intellectual property and expanding our product lines to include innovative tools for each step of the way, from early diagnosis to successful treatment, in the fight against cancer."
Biomoda has four U.S. patents and foreign patent rights in Canada, Japan, Mexico and Australia. Patent rights are pending before the European Patent Office.
Nanowire-based technology detects cancer-associated miRNAs in urine